Mnemo Therapeutics

Co-founded with Memorial Sloan Kettering Cancer Center, Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures. With its EnfiniT platform, a groundbreaking drug discovery engine, Mnemo applies a novel, integrated approach to cell therapy. Through precise identification of a new class of antigens with greater target specificity and the ability to efficiently reprogram T cells to increase their memory phenotype, as well as refine their engineering, Mnemo will transform the body’s immune response to overcome currently incurable diseases.

Year of creation: 2019

Line of business: Biotechnology

Institut Curie: Incubator, institutional co-founder and R&D partner

TECHNOLOGY

Mnemo is using its EnfiniT platform, an integrated drug discovery engine that combines:

• A proprietary combination of epigenetics tools assembled into powerful T cell engineering technologies
• A revolutionary target ID engine that sources newly-identified junctions between exons and transposable elements (JETs)
• Best-in-class manufacturing

APPLICATIONS

Mnemo is built by a transatlantic team of scientists and biotech leaders united in a quest to create the most powerful immune therapies to deliver accessible cures for all patients in need.

More about Mnemo Therapeutics:

• Institut Curie applauds the €75 million fundraising achieved by its spin-off Mnemo Therapeutics

• Immunotherapy: exploring the "grey genome" for new therapeutic targets

• Identification of a key enzyme for more effective and sustainable immunotherapies

• Immuno-oncology: Institut Curie and Mnemo Therapeutics highlight a new approach to identify unknown therapeutic targets